{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:30:05Z","timestamp":1792445405837,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10549-019-05214-y","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:50:50Z","timestamp":1557247850000},"page":"591-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"176","author":[{"given":"Hee Jun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"5214_CR1","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local\u2013regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483\u20132493","journal-title":"J Clin Oncol"},{"key":"5214_CR2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019\u20132027","journal-title":"J Clin Oncol"},{"key":"5214_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455\u20131461","journal-title":"JAMA"},{"key":"5214_CR4","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1245\/s10434-014-3775-6","volume":"21","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK (2014) Implementation of the American College of Surgeons Oncology Group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol 21:2468\u20132473","journal-title":"Ann Surg Oncol"},{"key":"5214_CR5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","volume":"20","author":"R Rouzier","year":"2002","unstructured":"Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304\u20131310","journal-title":"J Clin Oncol"},{"key":"5214_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599\u2013609","journal-title":"J Natl Cancer Inst"},{"key":"5214_CR7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25:3657\u20133663","journal-title":"J Clin Oncol"},{"key":"5214_CR8","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","volume":"23","author":"MC Green","year":"2005","unstructured":"Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983\u20135992","journal-title":"J Clin Oncol"},{"key":"5214_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM (2017) Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152:665\u2013670","journal-title":"JAMA Surg"},{"key":"5214_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.2696","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2018.2696","journal-title":"JAMA Surg"},{"key":"5214_CR11","doi-asserted-by":"crossref","unstructured":"Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608\u2013614; discussion 614\u2013616","DOI":"10.1097\/SLA.0000000000000924"},{"key":"5214_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","volume":"2","author":"KR Broglio","year":"2016","unstructured":"Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA (2016) Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol 2:751\u2013760","journal-title":"JAMA Oncol"},{"key":"5214_CR13","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-016-5277-1","volume":"23","author":"J Vila","year":"2016","unstructured":"Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS (2016) Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol 23:3501\u20133509","journal-title":"Ann Surg Oncol"},{"key":"5214_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1245\/s10434-018-6345-5","volume":"25","author":"O Kantor","year":"2018","unstructured":"Kantor O, Sipsy LM, Yao K, James TA (2018) A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 25:1304\u20131311","journal-title":"Ann Surg Oncol"},{"key":"5214_CR15","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1097\/MD.0000000000001720","volume":"94","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim S, Ryu J, Park S, Kim SI (2015) Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Medicine (Baltim) 94:e1720","journal-title":"Medicine (Baltim)"},{"key":"5214_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clbc.2013.12.015","volume":"14","author":"RJ Schipper","year":"2014","unstructured":"Schipper RJ, Moossdorff M, Nelemans PJ, Nieuwenhuijzen GA, de Vries B, Strobbe LJ, Roumen RM, van den Berkmortel F, Tjan-Heijnen VC, Beets-Tan RG, Lobbes MB, Smidt ML (2014) A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer. Clin Breast Cancer 14:315\u2013322","journal-title":"Clin Breast Cancer"},{"key":"5214_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","volume":"22","author":"P Cortazar","year":"2015","unstructured":"Cortazar P, Geyer CE Jr (2015) Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 22:1441\u20131446","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05214-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T19:22:57Z","timestamp":1588706577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["5214"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05214-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"6 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest to disclose in relation to the production of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to ethical tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea (IRB File No. 2017-09-051).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need for informed consent was waived because of the low risk posed by this investigation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}